News Lilly axes trial of Hanmi's arthritis drug Lilly may decide to develop drug in other indications
Views & Analysis Digital health round-up: online tool raises awareness of RA ... Richard Staines gives a round-up of the latest developments in digital health.
News Payday for AbbVie as Humira biosimilar delayed for five year... Deal with Amgen signals exclusivity until 2023 for mega-blockbuster
News FDA rejects J&J's sirukumab RA drug The FDA has rejected Johnson & Johnson’s next-generation rheumatoid arthritis drug, sirukumab, calling for more clinical data to evaluate its safety.
News Roche under pressure as second rituximab biosimilar filed in... Sandoz is following closely behind rival from Teva and Celltrion.
News Ready to pounce: Samsung joins Amgen with Humira biosimilar ... No-one can launch biosimilars until patent expires next year
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
